1,002 results match your criteria: "Groupement hospitalier EST[Affiliation]"
Ann Endocrinol (Paris)
January 2025
Hospices Civils de Lyon, Groupement Hospitalier Est, Endocrinology Federation, Lyon, France.
At present, primary hyperparathyroidism is most often discovered in an asymptomatic patient, but can sometimes be revealed by a renal or bone complications. In all cases, a full work-up is recommended, with assessment of renal function (glomerular filtration rate), 24-hour calciuria, screening for risk factors for lithiasis, and renal and urinary tract imaging (ultrasound or CT scan) to look for stones or nephrocalcinosis. Bone densitometry, with measurements of the spine, femur and radius, is the recommended reference test for demineralization.
View Article and Find Full Text PDFNeuro Oncol
December 2024
Genetics Department, Institut Curie, Paris, France.
Background: Medulloblastoma (MB) is one of the most prevalent embryonal malignant brain tumors. Current classification organizes these tumors into four molecular subgroups (WNT, SHH, Group 3, and Group 4 MB). Recently, a comprehensive classification has been established, identifying numerous subtypes, some of which exhibit a poor prognosis.
View Article and Find Full Text PDFAngiogenesis
December 2024
Service de Génétique et centre de reference de la maladie de Rendu-Osler, Hôpital Femme-Mère-Enfants, Hospices Civils de Lyon, Bron, France.
Epistaxis greatly affects patients with hereditary hemorrhagic telangiectasia (HHT). Although few systemic treatment exist, nintedanib, is a good candidate thanks to its anti-angiogenic activity. Our main objective was to evaluate the efficacy of oral nintedanib on epistaxis duration in HHT patients with moderate to severe epistaxis.
View Article and Find Full Text PDFDiabetes Ther
December 2024
Medtronic, Tolochenaz, Switzerland.
Introduction: The MiniMed™ 780G system uses an advanced hybrid closed loop algorithm to improve outcomes in people with type 1 diabetes (T1D). The MiniMed™ 780G Glycemic Control and Quality of Life (EQOL) study aimed to provide routine clinical practice data on system effectiveness and associated patient-reported outcomes (PROs) in France.
Methods: Individuals aged ≥ 7 years with T1D were enrolled.
Clin Chem Lab Med
December 2024
Fédération d'Endocrinologie, Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France.
J Neurol
December 2024
Service de Médecine Interne, Centre de Référence Des Maladies Héréditaires du Métabolisme, UMR INSERM 1253 « iBraiN », Université de Tours, CHU de Tours, Tours, France.
Background And Objective: Adult patients with early-treated phenylketonuria (AwET-PKU) may present some subtle neurocognitive deficits. The aim of the study was to investigate 1) neurocognitive functions in a large group of AwET-PKU 2) the influence of plasma phenylalanine (Phe).
Methods: Participants: 187 AwET-PKU (classic PKU [cPKU] 81%, mild PKU [mPKU] 14%, and mild persistent hyperphenylalaninemia [MPH] 5%).
Ann Endocrinol (Paris)
December 2024
LBMMS, centre de biologie et de pathologie Est, hospices civils de Lyon, groupement hospitalier Est, 69003 Lyon, France. Electronic address:
Purpose: Prolactin measurement is essential in endocrine diagnostics. Challenges such as the hook effect and reactivity to macroprolactin, which varies according to the reagent, complicate accurate measurement. The present study evaluated a newly marketed reagent to detect prolactin, IDS Prolactin, comparing it to an established reagent, Roche Elecsys Prolactin, assessing its behavior toward macroprolactin and polyethylene glycol (PEG) treatment, and establishing reference intervals.
View Article and Find Full Text PDFLancet Diabetes Endocrinol
January 2025
Department of Biostatistics and Epidemiology, Gustave Roussy, Paris, France; University Paris-Saclay, Paris, France; Office of Biostatistics and Epidemiology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Inserm, Université Paris-Saclay, CESP U1018, Oncostat, labelled Ligue Contre le Cancer, Villejuif, France.
Background: ESTIMABL2, a multicentre randomised phase 3 trial in patients with low-risk differentiated thyroid cancer (ie, pT1am or pT1b, N0 [no evidence of regional nodal involvement] or Nx [involvement of regional lymph nodes that cannot be assessed in the absence of neck dissection]), showed the non-inferiority of a follow-up strategy without radioactive iodine (I) administration compared with a postoperative I administration at 3 years post-randomisation. Here, we report a pre-specified analysis after 5 years of follow-up.
Methods: Patients treated with total thyroidectomy with or without prophylactic neck lymph node dissection, without postoperative suspicious findings on neck ultrasonography, were randomly assigned to the no-radioiodine group or to the radioiodine group (1·1 GBq-30 mCi after recombinant human thyrotropin-stimulating hormone).
J Exp Med
December 2024
Section of Paediatric Infectious Disease, Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
Multisystem inflammatory syndrome in children (MIS-C) is a rare condition following SARS-CoV-2 infection associated with intestinal manifestations. Genetic predisposition, including inborn errors of the OAS-RNAseL pathway, has been reported. We sequenced 154 MIS-C patients and utilized a novel statistical framework of gene burden analysis, "burdenMC," which identified an enrichment for rare predicted-deleterious variants in BTNL8 (OR = 4.
View Article and Find Full Text PDFChest
November 2024
INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Assistance Puplique - Hôpitaux de Paris (AP-HP), service de pharmacie, Hôpital Bicêtre, Le Kremlin Bicêtre, France; Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France; Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France. Electronic address:
Background: Trastuzumab emtansine has been recently suspected to be associated with the development of pulmonary arterial hypertension (PAH).
Research Question: Is there an association between trastuzumab, trastuzumab emtansine, or trastuzumab deruxtecan and the development of PAH?.
Study Design And Methods: Characteristics of incident PAH cases treated with trastuzumab, trastuzumab emtansine, or trastuzumab deruxtecan were analyzed from the French PH Registry, the VIGIAPATH program, concurrently with a pharmacovigilance disproportionality analysis using the World Health Organization pharmacovigilance database using a broad definition of pulmonary hypertension (PH) and a narrow definition of PAH.
Eur J Pediatr
November 2024
Pathophysiology, Diagnosis and Treatments of Bone Diseases, INSERM UMR1033, Lyon, France.
Unlabelled: Cystinosis metabolic bone disease (CMBD) is an emerging concept in infantile nephropathic cystinosis, patients presenting with bone pains, fractures, and deformations during teenage or early adulthood. The underlying mechanisms remain unclear. Our aim was to explore the pro-inflammatory profile of osteoclastic lineage in cystinotic patients.
View Article and Find Full Text PDFNeuromuscul Disord
December 2024
INMG-PGNM, UMR CNRS 5261 - INSERM U1315, Université Lyon 1, Lyon, France; Centre de Biotechnologie Cellulaire, Hospices Civils De Lyon, Lyon, France.
Hum Pathol
November 2024
Department of Pathology, Lyon Sud Hospital, Claude Bernard Lyon 1 University, Lyon, France; Université Lyon-1, EA 3738 CICLY, Oullins, France.
Cancers (Basel)
October 2024
Department of Neurosurgery, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677 Bron, France.
: The aim was to determine the complication rate and the predictors of complications and survival in high-grade glioma surgically managed at progression with implantation of Carmustine wafers. : A retrospective series of 53 consecutive patients operated on between 2017 and 2022 was built. : The median age was 55 ± 10.
View Article and Find Full Text PDFClin Chim Acta
January 2025
Biochimie et Biologie Moléculaire-LBMMS, Unité de diagnostic des pathologies dégénératives, Centre de Biologie et Pathologie Est, Groupement Hospitalier Est, Lyon, France; Equipe BIORAN, Centre de Recherche en Neurosciences de Lyon, CNRS UMR 5292, INSERM U1028, Université Lyon 1, Bron, France.
Objectives: Measurement of serum neurofilament light chain (sNfL) protein is becoming a key biomarker for many neurological diseases. Several immunoassays have been developed to meet these clinical needs, revealing significant differences in terms of variability and results. Here, we propose a French multicenter comparison of 5 sNfL assays.
View Article and Find Full Text PDFPLoS One
October 2024
Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, Bron, France.
Background: The aim of our study was to test different anesthetic mixtures in order to identify the most suitable one for a surgical cardiac ischemia-reperfusion model in mice.
Methods: 1) Sixty four mice were submitted to one of the 6 combinations of ketamine or alfaxalone associated to xylazine, medetomidine or midazolam. Depth and quality of anesthesia were evaluated via 5 reflex scores.
United European Gastroenterol J
November 2024
Gastroenterology and Endoscopy Unit, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.
Can J Anaesth
November 2024
University of Lyon, INSA-Lyon, Villeurbanne, France.
Int J Obes (Lond)
January 2025
Lyon Neuroscience Research Center (CRNL), CNRS UMR5292, INSERM U1028, Université Lyon 1, Lyon, France.
Elife
October 2024
Childhood Cancer & Cell Death (C3) team, LabEx DEVweCAN, Institut Convergence Plascan, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.
Ann Pathol
November 2024
Institut de pathologie des hospices civils de Lyon, groupement hospitalier Est, 59, boulevard Pinel, 69677 Bron cedex, France. Electronic address:
Thesaurismosis or storage diseases are rare genetic disorders due to an abnormal accumulation of an organic compound or its metabolite within cells. These conditions are either secondary to a defect in catabolism caused by enzymatic dysfunction or to a deficiency in transport proteins. They encompass lysosomal storage diseases, lipid storage diseases or dyslipidemias, and glycogen storage disorders or glycogenoses.
View Article and Find Full Text PDFAnn Biol Clin (Paris)
September 2024
Groupe de Travail « Sources d'Erreurs en Biologie Clinique », Société Française de Biologie Clinique, France, Laboratoire de Biochimie - Toxicologie, CHU de Rennes, 2 rue Henri Le Guilloux, 35000 Rennes, France.
Laboratory medicine plays a crucial role in patient care, contributing to approximately 70 % of clinical decisions. In collaboration with clinicians, laboratory medicine specialists perform analyses that are useful for diagnosis, screening and prevention. Laboratories are known for their efficiency, which is reached through a rigorous quality system.
View Article and Find Full Text PDFAJNR Am J Neuroradiol
September 2024
From the Inst. of Neuroradiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (T.A.); Dept. of Neuroradiology, University Hospital Augsburg, Germany (B.B.); Neuroradiological Reference Center for the pediatric brain tumor (HIT) studies of the German Society of Pediatric Oncology and Hematology, Faculty of Medicine, University Augsburg, Augsburg, Germany (B.B.); Service de Neurochirurgie B, CHU de Bordeaux, University of Bourdeaux, France (E.J.); Univ. Bordeaux, Bordeaux INP, CNRS, IMB, UMR 5251, Talence, France (E.J.); Institut de Pathologie Multisite-Site Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France (F.T., M.D., V.A.); Aix- Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (FB.D.); Dept. of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (G.E.); Dept. of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland (H.J.); Inst. of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (H.J.); Dept. of Pediatric Oncology/Hematology/Immunology, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany (K.E.); Murdoch Children's Research Inst., The Royal Children's Hospital, Flemington Road, Parkville, Victoria, Australia (L.LE); Children's Cancer Centre, The Royal Children's Hospital, Flemington Road, Parkville, Victoria, 3052, Australia (L.LE); Dept. of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia (L.LE); Crown Princess Victoria Children's Hospital, Linköping University Hospital, Linköping, Sweden (N.P.); Dept. of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden (N.P.); Dept. of Pediatric Oncology and Hematology, Skåne University Hospital, Lund University, Lund, Sweden (Ø.I); Dept. of Pediatrics, Pediatric Hematology and Oncology Ward, Kuopio University Hospital and Inst. of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (P.J.); Dept. of Clinical Pathology, Kuopio University Hospital and Unit of Pathology, Inst. of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (R.T.); Dept. of Neuro-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands (R.RE.); Dept. of Hematology-Oncology, Valley Children's Hospital, Madera, CA, USA (S.D.); Rare Cancers Genomics Team, Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France (S-O.A.); Inst. of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (W.A.K.); Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (W.A.K.); Dept. of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic (Z.J.); Division of Pediatric Glioma Research, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany (J.D.T.W., K.M.K.); Division of Pediatric Glioma Research (B360), German Cancer Research Center (DKFZ), Heidelberg, Germany (J.D.T.W., K.M.K.); National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Germany (J.D.T.W., K.M.K.); Dept. of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Inst. of Health, Berlin, Germany (V.H.K.); Dept. of Paediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark (V.H.K.); (European Society for Paediatric Oncology (SIOPE)-Brain Tumour Group.
Background And Purpose: CNS embryonal tumor with amplification (ET, PLAGL) is a newly identified, highly malignant pediatric tumor. Systematic MRI descriptions of ET, PLAGL are currently lacking.
Materials And Methods: MRI data from 19 treatment-naïve patients with confirmed ET, PLAGL were analyzed.
Environ Toxicol Pharmacol
October 2024
Clinical Investigation Centre, CIC 1407, Hospices Civils de Lyon-INSERM, Bron, France; Laboratoire de Biométrie et Biologie Evolutive, CNRS, UMR 5558, Université Lyon 1 Claude Bernard, Villeurbanne, France.
Endocrine disrupting chemicals (EDCs) may impact children's health, with medicines as a possible exposure source. Objective: to assess the potential impact of substances in paediatric medications and essential oils on children as EDC. It is a systematic review of five databases including Medline following the PECOT approach.
View Article and Find Full Text PDF